Greatmark Investment Partners Inc. Trims Stake in Johnson & Johnson (NYSE:JNJ)

Greatmark Investment Partners Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,440 shares of the company’s stock after selling 132 shares during the period. Johnson & Johnson accounts for about 2.4% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 15th biggest position. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $13,775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Hibernia Wealth Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $27,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $37,000. Tower View Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the period. Creative Capital Management Investments LLC lifted its stake in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at $48,000. 68.40% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Finally, Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $176.14.

View Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of JNJ opened at $156.76 on Monday. The company has a 50 day moving average of $158.20 and a two-hundred day moving average of $158.73. The company has a market cap of $377.37 billion, a price-to-earnings ratio of 11.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period last year, the business posted $2.35 earnings per share. The firm’s revenue was down 9.7% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.